删除或更新信息,请邮件至freekaoyan#163.com(#换成@)

A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves <i>in vivo

本站小编 Free考研考试/2022-01-02

Ciming Kang1,
Lin Xia1,2,
Yuanzhi Chen1,
Tianying Zhang1,
Yiwen Wang1,
Bing Zhou1,
Min You1,
Quan Yuan1,
Chi-Meng Tzeng2,
Zhiqiang An1,3,
Wenxin Luo1,,
Ningshao Xia1
1 State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Science, Xiamen University, Xiamen 361105, China;
2 Key Laboratory for Cancer T-Cell Theranostics and Clinical Translation(CTCTCT), Translational Medicine Research Center, School of Pharmaceutical Science, Xiamen University, Xiamen 361105, China;
3 Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
Funds: This work was financially supported by China Postdoctoral Science Foundation (No. 2016M600504). This work was also supported by Natural Science Foundation of Fujian Province (No. 2017J01066) and National Natural Science Foundation of China (Grant Nos. 31600748 and 81672111).






Abstract



PDF全文下载地址:

http://www.protein-cell.org/article/exportPdf?id=6928d389-916d-4b88-906d-77adec1de42f&language=en
相关话题/novel therapeutic antibody